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50 years ago, ophthalmologists thought glaucoma 
and increased intraocular pressure to be synonymous.1 
In 1958, Wolfgang Leydhecker deﬁ ned healthy limits 
for intraocular pressure1 and patients with intraocular 
pressure of 21 mm Hg or higher received a diagnosis of 
glaucoma, irrespective of whether there were any signs 
of glaucomatous damage. They were given intraocular-
pressure-lowering eye drops, and were told to use these 
drops three to four times a day or they would go blind. 
Patients with pressures of 20 mm Hg or lower were told 
that they did not have glaucoma.
The problem was that increased intraocular pressure and 
glaucoma are not synonymous. The ﬁ rst epidemiological 
study of glaucoma, done in Wales, UK in the 1960s, 
showed that many patients with glaucoma had 
intraocular pressure measurements within Leydhecker’s 
healthy range; these patients were said to have normal-
tension glaucoma.2 These ﬁ ndings have been conﬁ rmed 
in dozens of other epidemiological studies, and it is now 
accepted that about half of all patients with glaucoma 
have normal-tension glaucoma—a proportion as high 
as 90% in Japan.3 Equally confusingly, there were many 
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ageing of the population per se, that adds to pressure 
on health services and makes it harder to ﬁ nd the time 
for doing anything other than following treatment 
guidelines and meeting performance targets.
Yet feeling cared for is something that patients have 
always valued. In A Fortunate Man, an exploration 
of a general practitioner working in a deprived rural 
community in the 1960s, John Berger concluded that the 
physician was much valued by his patients not because 
of his clinical acumen, but because of his capacity to 
accompany people in their fear and anxiety.10 This brings 
us to the key issue of trust. To feel cared for is to trust. 
But trust is not just a quality of the relationship between 
a doctor and a patient. It is also a crucial dimension of 
a much broader set of relationships that citizens have 
with organisations, institutions, and government that is 
essential for societies to be able to function.11
The NHS is seen by many as a key national institution 
of value and trust, indeed, is emblematic of the sort of 
society we wish to live in. More attention needs to be 
given to the experience people have when they interact 
with it.12 Doing this cannot be achieved by endlessly 
pressing for greater eﬃ  ciencies, which assumes all 
things of importance can be monetised. A better 
deﬁ nition is needed of the value people place in the 
services that are established to treat and support the 
sick and the frail. Developing this deﬁ nition will require 
a rethink within the medical and caring professions 
about how the human dimension of care can become 
more central to training and practice, and deliberation 
of how far medical innovation should be deﬁ ned purely 
in terms of technological and pharmacological advance. 
However, none of these changes will be facilitated if the 
UK Government continues in the misguided belief that 
improving the value and trustworthiness of the NHS will 
be achieved by promoting distrust in the foundations of 
the institution and those who work in it.
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patients with pressures of 21 mm Hg or higher without 
glaucomatous damage, and when these patients were 
monitored without treatment for up to 20 years, most of 
them developed no signs of glaucomatous damage.4
Thus, ophthalmologists realised that the relation 
between increased intraocular pressure and glaucoma 
was not clear, which led to doubts about the eﬃ  cacy 
of intraocular-pressure-lowering therapy. Because this 
uncertainty was an obstacle to clinical decision making 
and to allocation of suﬃ  cient resources for glaucoma 
care, clinical studies were needed. The problem was ﬁ rst 
addressed in four randomised clinical trials in the 1980s5–8 
that investigated whether a reduction of intraocular 
pressure in patients with increased pressure in the 
absence of glaucomatous damage (ocular hypertension) 
could reduce the incidence of glaucoma damage. Results 
were inconclusive,5–8 and a 1989 report commissioned by 
the US Congress concluded that there was no proof that 
lowering of intraocular pressure reduced glaucomatous 
damage. Investigators then started two randomised 
controlled studies of patients with manifest glaucoma. 
The Collaborative Normal-Tension Glaucoma Study 
(CNTGS) enrolled only patients with normal-tension 
glaucoma, whereas the Early Manifest Glaucoma Trial 
(EMGT) studied patients with glaucoma who had normal 
and increased pressures; both trials compared pressure-
lowering treatment with no treatment. The intention-
to-treat analysis in CNGTS did not report signiﬁ cant 
eﬀ ects, but after correction for the increased incidence 
of cataract in the treated group, the researchers reported 
positive treatment eﬀ ects.9 Findings from EMGT showed 
that pressure lowering had positive eﬀ ects, irrespective 
of patients’ initial intraocular pressures.10
In The Lancet, David Garway-Heath and colleagues11 
report results of the United Kingdom Glaucoma 
Treatment Study (UKGTS), a randomised clinical trial to 
investigate the eﬀ ects of intraocular pressure lowering 
in glaucoma patients with healthy pressures. UKGTS 
involved ten centres in the UK, in which 516 patients were 
randomly assigned. In some ways, UKGTS was modelled 
on the EMGT—eg, the original primary outcome (which 
was later amended), but the two studies also diﬀ ered 
in several respects. First, UKGTS was placebo controlled 
and EMGT was not. Second, UKGTS used monotherapy 
in the treatment group—prostaglandin analogue eye 
drops (latanoprost 0·005%), the most commonly used 
antiglaucoma therapy in high-income countries. The 
authors also aimed to use a study design from which 
conclusions could be drawn in a relatively short time—
patients were followed up for only 2 years. To achieve 
this, 11 visual ﬁ eld tests were obtained during this period, 
since it is well known that identiﬁ cation of visual ﬁ eld 
progression or measurement of rate of progression needs 
several ﬁ eld tests, and that the time needed to identify 
progression strongly depends on the frequency of testing.
Garway-Heath and colleagues’ study11 is important 
in many ways, perhaps most importantly because it is 
the second to show the positive treatment eﬀ ects of 
intraocular pressure reduction in manifest glaucoma. 
For the highest level of medical evidence, more than 
one study is usually required and this has been absent in 
the area until now. Since modern glaucoma treatment 
is based on reduction of intraocular pressure, and 
because glaucoma management uses about 25% of all 
ophthalmology resources, this is a fundamental issue in 
ophthalmic care. That the study was placebo controlled 
is a further strength.
The magnitude of treatment eﬀ ects is also important. 
The intraocular pressure diﬀ erence between the 
treated and the placebo groups after 24 months was 
slight (2·9 mm Hg), due to the fact that untreated 
pressures at study entry were quite low. Intraocular-
pressure-reducing drugs produce much smaller pressure 
reductions in eyes that start with low pressures than in 
eyes in which pressure is high. Still, the risk of progression 
was substantially lower in the treated group than in the 
group receiving placebo drops (adjusted hazard ratio 
[HR] 0·44 [95% CI 0·28–0·69]). From this HR, the risk 
reduction could be about 19% per mm Hg, conﬁ rming 
results from the EMGT and Canadian Glaucoma Study, 
and showing that intraocular pressure reduction is highly 
eﬀ ective, and that every mm of pressure counts.12,13 
These results should motivate careful clinical follow-up 
and monitoring of disease progression in patients with 
glaucoma, and should also serve as a stimulus to the 
pharmaceutical industry to continue development of 
new and even more potent drugs.
It is important that Garway-Heath and colleagues11 
documented very signiﬁ cant treatment eﬀ ects after 
only 24 months; in fact, the ﬁ rst diﬀ erences were seen 
after 12 months (adjusted HR 0·47; 95% CI 0·23–0·95). 
Certainly, the UKGTS took a lot longer than 2 years to 
complete, but only because recruitment took several years. 
Measurement of glaucomatous progression with visual 
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Completion of the ﬁ rst reference human genomes, now 
nearly 15 years ago, was a mammoth achievement. 
Expectations were high and predictions of revolutionary 
eﬀ ects on science, and medical practice in particular, 
justiﬁ able. However, we had to wait another 5 years to 
read individual genomes aﬀ ordably, and another 5 years 
before we started to use the information to address the 
genetics of rare human diseases. The past 5 years have 
been spectacular, with almost daily novel gene discoveries, 
not only for rare mendelian diseases but also for 
complex and multifactorial disorders. With the collected 
knowledge from the tens of thousands of individuals’ 
exomes and genomes available, and the thousands 
now being generated daily worldwide, we have come to 
realise the vastness of individually rare genetic variation 
in human genomes. We have learned much about the 
frequency of de-novo mutations and their relevance 
to disease. In particular, study of neurodevelopmental 
diseases such as intellectual disability,1 autism,2 epilepsy,3 
and schizophrenia4 has beneﬁ ted, together with that of 
cancers.5 Several excellent how-to exome guides, most of 
which tackle the diﬃ  cult tasks of sorting pathogenic from 
non-pathogenic DNA and protein variants, using disease 
inheritance models or a de-novo mutation hypothesis 
combined with an appropriate selection of bioinformatics 
tools and laboratory validation methods, have been 
proposed.6–8 With these approaches, genome-scale 
sequencing technologies are ﬁ nally entering medical 
practice more broadly as unifying tests for diagnosis of 
genetic disorders.
In The Lancet, Caroline Wright and colleagues9 report a 
robust and scalable diagnostic whole exome sequencing 
workﬂ ow, and its practical use when applied to data 
for 1133 patients collected as part of the Deciphering 
Developmental Disorders (DDD) study in the UK. The 
report outlines the processes taken from recruitment, 
data management, and processing, the choices made to 
do both automatic and manual variant ﬁ ltering of around 
80 000 variants per individual, and the framework for 
reporting results. Great care has been taken at every 
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ﬁ eld status is the gold standard, and visual ﬁ eld sensitivity 
is also important to patients. Nevertheless, in recent years 
some researchers have stated that studies using visual 
ﬁ eld endpoints take too long, and that it is too diﬃ  cult 
to assess the eﬀ ects of new drugs or other treatments. 
Garway-Heath and colleagues clearly show that this view 
is pessimistic, and that, with frequent testing with widely 
available clinical instruments, important studies can be 
completed within a very reasonable time. I expect this to 
be the ﬁ rst of a series of papers reporting UKGTS results; 
additional ﬁ ndings will be reported in future, notably 
those that compare the results obtained with visual ﬁ eld 
testing with those of ophthalmic image analysis. 
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